Login / Signup

Peripheral nervous system adverse events associated with immune checkpoint inhibitors.

Simone RossiFrancesco GelsominoRita RinaldiLorenzo MuccioliFrancesca ComitoAlessandro Di FedericoAndrea De GiglioGiuseppe LambertiElisa AndriniVeronica MollicaRoberto D'AngeloFlavia BaccariCorrado ZenesiniPierandrea MadiaEmanuel RaschiPietro CortelliAndrea ArdizzoniMaria Guarino
Published in: Journal of neurology (2023)
In our large cohort of ICI-treated patients, 2.17% developed PNS-irAEs. Compared to ir-neuropathies, ir-MG/myositis tend to occur earlier from ICI exposure and present a worse response to treatment and a higher mortality.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • type diabetes
  • patient reported outcomes
  • combination therapy
  • interstitial lung disease